Novartis Ag NVS
We take great care to ensure that the data presented and summarized in this overview for NOVARTIS AG is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NVS
View all-
Dodge & Cox San Francisco, CA12.2MShares$1.18 Billion0.85% of portfolio
-
Primecap Management CO Pasadena, CA12MShares$1.16 Billion1.03% of portfolio
-
Dimensional Fund Advisors LP Austin, TX8.09MShares$784 Million0.23% of portfolio
-
Morgan Stanley New York, NY6.98MShares$676 Million0.06% of portfolio
-
Loomis Sayles & CO L P5.77MShares$559 Million0.87% of portfolio
-
Bank Of America Corp Charlotte, NC4.96MShares$481 Million0.05% of portfolio
-
Franklin Resources Inc San Mateo, CA4.38MShares$424 Million0.15% of portfolio
-
Wellington Management Group LLP Boston, MA4MShares$387 Million0.08% of portfolio
-
Goldman Sachs Group Inc New York, NY3.49MShares$338 Million0.07% of portfolio
-
Janus Henderson Group PLC London, X02.54MShares$246 Million0.16% of portfolio
Latest Institutional Activity in NVS
Top Purchases
Top Sells
About NVS
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Insider Transactions at NVS
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|